For The Patient
Hemispherx Biopharma, Inc. has developed over nearly three decades a vast body of knowledge relating to a potentially new class of pharmaceutical products (nucleic acid compounds) that are designed to activate otherwise dormant cellular defenses against viruses and tumors. We pursue commercialization of our products and have a strong and broad-based patent base.
Hemispherx Drug Candidates
Ampligen®, the company's lead compound addresses a variety of chronic diseases and viral disorders. Ampligen® drugs for several viral disorders are under development. More than 40,000 doses at over 20 U.S. clinical trial sites have been delivered with Ampligen®. A strategic relationship with Temple University provides the Company with access to a potential "pill form" of a group of other potential antiviral drugs, termed Oragens. Oragens are presently at a preclinical stage of development.
To serve the patient community, we have prepared general information on certain diseases for which Hemispherx, or its partners, have research programs underway, or have conducted preliminary clinical trials in the United States. To complement this information we have provided relevant references to useful resource sites at the bottom of each page. Please visit this page periodically as facts on additional information may be added. See the links to the right for information on Chronic Fatigue Syndrome, HIV, hepatitis B, hepatitis C, renal cell carcinoma, and metastatic malignant melanoma.
|
